Tilray’s Aphria RX GmbH Subsidiary Completes First Successful Harvest and Delivery of Medical Cannabis Grown in Germany
Tilray, Inc. (NASDAQ | TSX: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that its wholly-owned subsidiary in Germany, Aphria RX GmbH, has completed the first successful harvest of medical cannabis cultivated in Germany for distribution to German pharmacies. The medical cannabis harvest is the first cultivated under European Good Manufacturing Practices (EU GMP) standard at Tilray’s state-of-the-art 6,000 square meter indoor growing facility in Neumünster, Germany. The subsequent distribution, which was carried out by a distributor on behalf of the German Cannabis Agency and in accordance with all pharmaceutical and narcotic legal requirements, underscores Tilray’s strong foothold and operational excellence within Europe’s key medical cannabis market.
“Our harvest in Germany represents an important milestone in granting access to high-quality and trustworthy medical cannabis to patients and healthcare professionals in Germany,” said Denise Faltischek, Tilray's Head of International and Chief Strategy Officer. “It is a testament to the professionalism and dedication of our team that, despite the challenges of a global pandemic, we remained on track as the first licensed producer to cultivate medical cannabis in Germany. Our achievement would not have been possible without the trust and cooperation of the Federal Institute for Drugs and Medical Devices (BfArM) and the Germany Cannabis Agency, for which we are sincerely grateful.”
Since Germany’s Cannabis as Medicines Act was enacted in March 2017, the country has relied exclusively on imports to meet the growing medical demand currently estimated at well over 100,000 patients. Tilray’s ongoing domestic harvest and production will play an indispensable role in ensuring that patient needs are met with products of the highest quality medical cannabis while at the same time reducing dependence on imported supply.
Irwin D. Simon, Tilray’s Chief Executive Officer, added, “The European Union represents a powerful growth market for us and, among its constituent markets, Germany possesses the greatest potential. We look forward to leveraging our strong medical platform and our multifaceted international operation, which combines in-country cultivation, importation, and large distribution infrastructure, to increase access and availability to high-quality, consistent medical cannabis for all European patients.”
Mr. Simon concluded, “Tilray’s achievement in Germany serves as a strong affirmation that we are competitively differentiated by scale and proven execution skills. As a result, we are poised to transform the industry globally with our highly scalable footprint, portfolio of diverse medical cannabis brands, and compelling products that respond to a wide range of patient and consumer needs. The E.U. is central to our worldwide distribution network, and we look forward to accelerating our progress.”
Tilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from Canada and import medical cannabis products into the E.U. in 2016.
Tilray Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For media inquiries, please contact:
For investor inquiries please contact:
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LiquidPower Specialty Products Inc. and Subsea 7 Acquire Interest in Safe Marine Transfer, LLC29.7.2021 12:00:00 CEST | Press release
Safe Marine Transfer, LLC. (SMT) announced that LiquidPower Specialty Products Inc. (LSPI) has taken an equity interest in SMT and has entered a strategic alliance to deliver LSPI’s market leading drag reducing agents (DRA) subsea via SMT’s patented all electric dual barrier subsea storage and delivery technologies. Drag reducing agents (DRA), also known as flow improvers, are long-chain hydrocarbon polymers that act as turbulence inhibitors along the pipe wall to decrease the amount of energy lost in turbulent activity. The introduction of DRA at the subsea well/drill center has the potential to significantly increase production in a cost-effective manner, by increasing flow rates in existing subsea production lines, subsea gathering lines, and subsea trunk lines. Marina Kaplan, LSPI’s Vice President of Strategy and Corporate Development, “SMT presents LSPI with a unique opportunity to leverage over four decades of pioneering technology, product development and global delivery to a co
Inmarsat Unveils the Communications Network of the Future29.7.2021 11:47:00 CEST | Press release
Today, Inmarsat unveiled plans for ORCHESTRA, the communications network of the future. In the largest ever transformation of its current world-class services, Inmarsat ORCHESTRA will bring together existing geosynchronous (GEO) satellites with low earth orbit satellites (LEO) and terrestrial 5G into an integrated, high-performance solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005443/en/ Inmarsat unveils ORCHESTRA, the communications network of the future (Graphic: Business Wire) Whether for a ship in a crowded port, an aircraft preparing to land at LAX, or a defence force deployed in a remote location, ORCHESTRA is designed to meet evolving connectivity needs in the mobility market with a service unmatched by any competitor offering, planned or in existence. “An orchestra brings different instruments together, each supporting the other and playing its role in the masterpiece. We’re building ORCHESTRA on the
ABP Publishing Exceeded 500 Audiobooks in Its Catalogue, and Sales Are Forecasted to Grow 30% in 202129.7.2021 10:30:00 CEST | Press release
ABP Publishing announces its audiobook catalogue exceeded 500 titles. The European publisher go on to say that they are forecasting a 100% increase in titles (1000 titles) by 2024. In addition, a 30% increase in total sales is predicted before the end of 2021, continuing a five-year trend of growth. There are plans to publish 17% more titles in 2022 and continue growing the catalogue to meet their 100% increase target by 2024. To meet these targets, ABP Publishing plans to expand its presence gradually in markets it entered recently, such as Turkey, Japan, Korea, and Spain. Additionally, it will continue to work with local authors, particularly in Germany and France. "For the last three years, ABP Publishing has shown solid growth in sales and production. It means that we managed to create an effective system of acquiring rights to high-potential books and externalizing them into good quality audiobooks. I believe the combination will help us achieve our main aim during the next three
Henley & Partners: Investment Migration: “We Need More, Not Less Immigration of People Who Contribute Positively to Society”29.7.2021 10:00:00 CEST | Press release
Henley & Partners Chairman Dr. Christian H. Kaelin says the significant worldwide expansion of investment migration, by which affluent individuals invest in other countries to acquire residence or citizenship, is simply unstoppable. Speaking at The World Ahead Gala Dinnerhosted by The Economist in Athens last week, Dr. Kaelin stated that all over the world countries have realized the importance of residence and citizenship to attract much-needed foreign direct investment, debt-free capital, talented entrepreneurs, and experienced investors. Dr. Kaelin, who is widely considered the pioneer and one of the world’s foremost experts in investment migration, shared the stage with Ireland’s Minister for Finance and President of the Eurogroup, Paschal Donohoe, and Greece’s Minister of Finance, Christos Staikouras, at the annual event to discuss the year ahead with government and business leaders. Further accelerated by the need to alleviate the financial distress following the Covid-19 pandemi
Katherine Alexakis Appointed to Chief Financial Officer of euNetworks29.7.2021 10:00:00 CEST | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the appointment of Katherine Alexakis to the leadership team, taking up the role of Chief Financial Officer. This appointment is effective 6 September 2021, at which time Katherine will also join the Board of Directors as an Executive Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005060/en/ Brady Rafuse, CEO of euNetworks (Photo: Business Wire) Katherine joins euNetworks after 15 years working at Goldman Sachs International in London, where she held several roles across the European Equities business. She most recently served as a Managing Director within European Equity Research, sitting on the European Investment Review Committee and leading the European Tactical Research Group. Katherine was also responsible for merchandising the research product across the Securities division. Previously, Katheri
Onera raises €10.5M in Series B funding29.7.2021 10:00:00 CEST | Press release
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed the Series B funding round today, which brought the total funding raised to date above the €24M mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005036/en/ The model is wearing the head and chest patch of Onera STS innovative PSG system. (Photo: Business Wire) Led by Innovation Industries in close collaboration with Invest-NL and with existing investors Jazz Pharmaceuticals, imec.xpand, BOM and 15th Rock, the company intends to use the funds to execute clinical studies and further commercialize its sleep diagnostics and monitoring products in Europe and the United States. Onera has recently obtained the CE mark for its first product, an innovative polysomnography (PSG) system that brings the gold-standard quality of a hospital diagnostic system directly to a user’s home. “We’re going to leverage the funding to conduct progressively larger s
Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology29.7.2021 10:00:00 CEST | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger will lead the advancement of Prokarium’s oncology pipeline into the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005044/en/ Uz Stammberger, MD, Chief Medical Officer of Prokarium (Photo: Business Wire) “Uz brings extensive clinical experience to Prokarium’s team having spent more than two decades in oncology drug development and research,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “We are thrilled to welcome Uz onboard as we expand our clinical portfolio into oncology, and I look forward to working together on the development of our next generation immuno-oncology pipeline.” “Prokarium’s unique technology based on live, attenuated bacteria is a promising and powerful strategy for